Werewolf Therapeutics, Inc. (HOWL)

USD 1.48

(-9.76%)

Market Cap (In USD)

65.95 Million

Revenue (In USD)

19.94 Million

Net Income (In USD)

-37.36 Million

Avg. Volume

277.88 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.45-8.194
PE
-
EPS
-
Beta Value
0.414
ISIN
US95075A1079
CUSIP
95075A107
CIK
1785530
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Daniel J. Hicklin Ph.D.
Employee Count
-
Website
https://werewolftx.com
Ipo Date
2021-04-30
Details
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.